Fonda Bravo v. HHS - Influenza, Guillain-Barré Syndrome (2017)
Case summary [AI summaries can sometimes make mistakes]
Fonda Bravo filed a petition for compensation under the National Vaccine Injury Compensation Program on January 30, 2017, alleging that she suffered Guillain-Barré Syndrome (GBS) as a result of receiving an influenza vaccine on September 23, 2015. Petitioner asserted that the vaccine was administered in the United States, that she experienced residual effects for more than six months, and that there had been no prior award or settlement for civil action damages.
The respondent denied that the flu vaccine caused her GBS or any other injury. Nevertheless, on January 30, 2017, the parties filed a joint stipulation for compensation.
Chief Special Master Nora Beth Dorsey found the stipulation reasonable and adopted it as the decision of the Court. Fonda Bravo was awarded a lump sum of $83,736.00 as compensation for all damages.
Maximillian J. Muller represented the petitioner, and Claudia B.
Gangi represented the respondent. The public decision does not describe the specific onset of symptoms, diagnostic tests, treatments, or expert witnesses.
Theory of causation
Petitioner Fonda Bravo alleged Guillain-Barré Syndrome (GBS) following an influenza vaccine administered on September 23, 2015. The respondent denied causation. The parties filed a joint stipulation for compensation, which was adopted by Chief Special Master Nora Beth Dorsey. Petitioner was awarded $83,736.00. The public decision does not detail the specific theory of causation, mechanism, or any expert testimony. The case was handled by Muller Brazil, LLP for the petitioner and the U.S. Department of Justice for the respondent.
Source PDFs
USCOURTS-cofc-1_16-vv-00679